Cardiometabolic & kidneyRandomised controlled trial
Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes
- Randomised crossover trial
- open-label
- 8-week washout
Authors' conclusion
Liraglutide treatment resulted in improved myocardial perfusion, energetics, and 6-minute walk distance in patients with T2D, whereas pioglitazone showed no effect on these parameters
Study context
- Population
- Patients with T2DM without CVD
- Participants
- 41 patients
- Comparison
- Liraglutide vs pioglitazone
Primary result
As reported in the abstract
Myocardial perfusion, energetics and 6-minute walk distance (before vs after treatment) · 16 weeks
- Liraglutide: stress myocardial blood flow 1.62 to 2.08 mL/g/min
- P = 0.01
- Liraglutide: myocardial perfusion reserve 2.40 to 2.90
- P = 0.01
- Liraglutide: rest phosphocreatine/ATP ratio 1.47 to 1.94
- P =0.00002
- Liraglutide: stress phosphocreatine/ATP ratio 1.32 to 1.58
- P = 0.004
- Liraglutide: 6-minute walk distance 488 m to 521 m
- P = 0.009
- Pioglitazone: Left ventricular (LV) mass 96 g to 105 g
- P = 0.003
- Pioglitazone: mitral-inflow E/A ratio 1.04 to 1.34
- P = 0.008
- Pioglitazone: LV concentricity index 0.79 to 0.73 mg/mL
- P = 0.04
Original publication
Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes. J Am Coll Cardiol. Published 6 August 2024. doi:10.1016/j.jacc.2024.04.064
Summarised from the published abstract; every number is checked against it